Compare Fidelity National Information Servcs Inc (FIS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Sanofi SA — how do they compare? Fidelity National Information Servcs Inc trades at $34.08 (market cap $17.71B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 5.4× Fidelity National Information Servcs Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Sanofi SA for 94 Days on average.
| FIS | SNY | |
|---|---|---|
Market Cap | $17.71B | $95.18B |
Volume | 9,047,825 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $68.57 | $52.34 |
52-Week Low | $32.44 | $39.51 |
Typical Hold Time | 88 Days | 94 Days |
Enterprise Value | $38.22B | $114.48B |
Dividend Yield | 5.13% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.04, up 0.65% on the day, with a bearish technical signal from moving averages and oscillators. The company's valuation metrics appear attractive with a P/E of 5.27 and P/S of 1.46, while recent earnings have shown beats in Q1 and Q2 2026. Revenue is projected to grow to $12.2B in 2026, with net income margin improving to 27.64%. Recent news highlights contract wins and platform modernizations, supporting growth momentum.
The outlook for FIS is cautiously optimistic, with strong analyst support (56.76% buy ratings) and a consensus price target of $47.15 implying significant upside. However, risks include a high debt-to-asset ratio of 39.06% in 2025 and volatile cash flow trends. Investors should weigh the low valuation against execution risks and macroeconomic pressures in the financial technology sector.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
